Wolfgang Miesbach: Roctavian Experience in Modern Hemophilia Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Flora Peyvandi et al., published in RPTH, adding:
“From a ‘haemophilia‑free mind’ to future‑ready care: why gene therapy treaters’ Roctavian experience still matters.
10 haemophilia gene therapy treaters from Germany, Italy and the United States share their real‑world experience with more than 25 adults with severe haemophilia A who received valoctocogene roxaparvovec (Roctavian):
- How they identify and prepare candidates (AAV5 testing, liver assessment, shared decision‑making)
- How centres and multidisciplinary teams are set up (including hub‑and‑spoke models, telemedicine and social work support)
- What actually happens on ‘infusion day’ and in the weeks afterwards
- How long‑term FVIII and liver monitoring is organised and how ALT rises are managed with steroids.
Why is this still important, even though Roctavian will no longer be available?
- The infrastructure they have built – hub‑and‑spoke networks, remote monitoring and close collaboration with hepatology and psychology – will underpin future programmes.
- Patients’ experiences (freedom from prophylaxis, fewer injections, greater independence, easier travel) and their concerns (FVIII durability, liver health, monitoring burden) offer valuable insights for future gene therapy discussions.
- Their collective message: many perceived barriers (approvals, logistics, training) proved manageable once clear pathways and communication structures were in place.”
Title: Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec
Authors: Flora Peyvandi, Robert Klamroth, Johannes Oldenburg, Anita Rajasekhar, Andrea Buxton, Matteo Nicola Dario Di Minno, Saskia Gottstein, Amit Soni, Ezio Zanon, Andrew D. Leavitt
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 25, 2026, 10:49Onisillos Sekkides: Quantifying Maternal IgG Against Group B Streptococcus Alpha-Like Proteins in Neonates
-
Jun 25, 2026, 05:26Paola Mendez Hiraldo: Glenn Ruperto’s Stroke Recovery and the Power of Team-Based Care
-
Jun 25, 2026, 05:19Steven Bell: Lessons in Rapid Stroke Care from Vall d’Hebron University Hospital
-
Jun 25, 2026, 04:48Brianne Martin: Stroke Recovery Is More Than Medical Appointments
-
Jun 24, 2026, 22:30The Clinical Impact of Anaphylaxis-Associated Coagulopathy – JTH
-
Jun 24, 2026, 21:08Martin Haluzík: Semaglutide as a Strategy for Primary Prevention of Cerebrovascular Disease in RA
-
Jun 24, 2026, 19:43New ASH/ISTH 2026 Guidelines for Pediatric Anticoagulant Prophylaxis of VTE Are Now Live – Blood Journals Portfolio
-
Jun 24, 2026, 18:36Maryam Sardar: Timely Anticoagulation in SMV Thrombosis Complicating Acute Pancreatitis
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia